Amgen Selects Illumina Technology for Landmark Women's Health Study with Brigham & Women's Hospital.
Illumina Inc. announced an agreement with Amgen for the purchase and installation of a large, multi-component genetic analysis system for Infinium genotyping. Amgen, in collaboration with the Brigham & Womens Hospital will use Illumina technology to analyze approximately 28,000 samples at Amgens facility in Cambridge, Massachusetts as part of the Womens Genome Health Study. The study will look at genetic variation in American women that may underlie a range of serious illness such as heart disease, stroke, diabetes, breast cancer and osteoporosis.
